Astellas Pharma Inc. (4503)

Basic

  • Market Cap

    ¥3,210.13B

  • EV

    ¥3,738.39B

  • Shares Out

    1,792.87M

  • Revenue

    ¥1,523.57B

  • Employees

    14,484

Margins

  • Gross

    81.62%

  • EBITDA

    17.31%

  • Operating

    10.21%

  • Pre-Tax

    4.2%

  • Net

    2.23%

  • FCF

    12.75%

Returns (5Yr Avg)

  • ROA

    7.23%

  • ROE

    11.46%

  • ROCE

    16.15%

  • ROIC

    12.43%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • EV/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    ¥2,610

  • P/E

  • EV/Sales

  • EV/EBITDA

  • EV/FCF

Per Share

  • Rev

    ¥844.14

  • Earnings (Dil)

    ¥18.73

  • FCF

    ¥107.2

  • Book Value

    ¥914.38

Growth (CAGR)

  • Rev 3Yr

    6.37%

  • Rev 5Yr

    3.1%

  • Rev 10Yr

    3.45%

  • Dil EPS 3Yr

    -37.02%

  • Dil EPS 5Yr

    -27.59%

  • Dil EPS 10Yr

    -5.33%

  • Rev Fwd 2Yr

    4.99%

  • EBITDA Fwd 2Yr

    33.4%

  • EPS Fwd 2Yr

    43.58%

  • EPS LT Growth Est

    26.35%

Dividends

  • Yield

  • Payout

    345.56%

  • DPS

    ¥65

  • DPS Growth 3Yr

    16.6%

  • DPS Growth 5Yr

    11.93%

  • DPS Growth 10Yr

    9.6%

  • DPS Growth Fwd 2Yr

    11.95%

Select a metric from the list below to chart it

Mar '14
Mar '16
Mar '18
Mar '20
Mar '22
LTM

Total Revenues

1,306,348.0

1,300,843.0

1,249,528.0

1,296,163.0

1,518,619.0

1,523,572.0

Total Revenues % Chg.

0.5%

-0.4%

-3.9%

3.7%

17.2%

8.3%

Cost of Goods Sold, Total

292,050.0

276,739.0

246,063.0

253,009.0

288,353.0

280,061.0

Gross Profit

1,014,298.0

1,024,104.0

1,003,465.0

1,043,154.0

1,230,266.0

1,243,511.0

Selling General & Admin Expenses, Total

490,263.0

499,295.0

504,316.0

548,840.0

630,272.0

669,778.0

R&D Expenses

208,682.0

224,226.0

224,489.0

246,010.0

276,128.0

278,898.0

Depreciation & Amortization

35,212.0

21,164.0

23,763.0

28,283.0

38,436.0

52,202.0

Other Operating Expenses

-2,275.0

11,936.0

-35.0

1,876.0

53,778.0

87,086.0

Other Operating Expenses, Total

731,882.0

756,621.0

752,533.0

825,009.0

998,614.0

1,087,964.0

Operating Income

282,416.0

267,483.0

250,932.0

218,145.0

231,652.0

155,547.0

Interest Expense, Total

-2,232.0

-2,118.0

-2,315.0

-3,217.0

-4,302.0

Interest And Investment Income

2,770.0

2,248.0

760.0

862.0

5,253.0

6,910.0

Net Interest Expenses

2,770.0

16.0

-1,358.0

-1,453.0

2,036.0

2,608.0

Income (Loss) On Equity Invest.

-1,627.0

-1,660.0

478.0

489.0

1,260.0

-756.0

Currency Exchange Gains (Loss)

735.0

-8,928.0

-2,332.0

8,172.0

-10,124.0

-10,124.0

Other Non Operating Income (Expenses)

2,286.0

1,342.0

72.0

-2,431.0

2,303.0

2,305.0

EBT, Excl. Unusual Items

286,580.0

258,253.0

247,792.0

222,922.0

227,127.0

149,580.0

Restructuring Charges

-19,678.0

-1,829.0

-9,293.0

-19,556.0

-4,510.0

-4,510.0

Gain (Loss) On Sale Of Investments

5,812.0

10,558.0

5,084.0

-5,007.0

-5,007.0

Gain (Loss) On Sale Of Assets

3,923.0

24.0

24,234.0

212.0

9,457.0

Asset Writedown

-11,446.0

-13,796.0

-101,746.0

-74,850.0

-83,964.0

-83,964.0

Legal Settlements

-12,301.0

-1,201.0

-2,012.0

-948.0

-1,497.0

-1,497.0

EBT, Incl. Unusual Items

248,967.0

245,350.0

145,323.0

156,886.0

132,361.0

64,059.0

Income Tax Expense

26,702.0

49,939.0

24,734.0

32,800.0

33,647.0

30,109.0

Earnings From Continuing Operations

222,265.0

195,411.0

120,589.0

124,086.0

98,714.0

33,950.0

Net Income

222,265.0

195,411.0

120,589.0

124,086.0

98,714.0

33,950.0

Net Income to Common Incl Extra Items

222,265.0

195,411.0

120,589.0

124,086.0

98,714.0

33,950.0

Net Income to Common Excl. Extra Items

222,265.0

195,411.0

120,589.0

124,086.0

98,714.0

33,950.0

Total Shares Outstanding

1,885.8

1,857.5

1,853.0

1,827.1

1,796.8

1,792.9

Weighted Avg. Shares Outstanding

1,931.9

1,876.2

1,857.1

1,849.7

1,820.0

1,804.9

Weighted Avg. Shares Outstanding Dil

1,933.7

1,877.5

1,858.2

1,850.6

1,825.1

1,812.5

EPS

115.1

104.2

64.9

67.1

54.2

18.8

EPS Diluted

114.9

104.1

64.9

67.1

54.1

18.7

EBITDA

345,874.0

333,879.0

323,584.0

297,829.0

337,390.0

263,774.0